Efficacy and safety of pharmacological treatments for restless legs syndrome in hemodialysis patients: a systematic review and meta-analysis - Report - MDSpire
Advertisement
Efficacy and safety of pharmacological treatments for restless legs syndrome in hemodialysis patients: a systematic review and meta-analysis
Effectiveness and Safety of Drug Therapies for Restless Legs Syndrome in Patients Undergoing Hemodialysis
Overview
This systematic review and meta-analysis evaluated the efficacy and safety of pharmacological therapies for Restless Legs Syndrome (RLS) in adults undergoing hemodialysis. Gabapentinoids were found to be the most effective treatment, significantly improving RLS symptoms, sleep quality, and quality of life, while also noting an increase in adverse events associated with dopaminergic agents.
Background
Restless Legs Syndrome (RLS) is a prevalent condition among patients undergoing hemodialysis, significantly impacting their sleep and quality of life. The condition is often underreported in this population, leading to a lack of effective management strategies. Understanding the efficacy and safety of available pharmacological treatments is crucial for improving patient outcomes in this vulnerable group.
Data Highlights
Outcome
Effect Size
IRLS Score Improvement
MD –7.84
Sleep Quality Improvement
SMD –0.82
Quality of Life Improvement
SMD 0.48
Adverse Events Increase
RR 1.28
Key Findings
Pharmacologic therapy significantly improved IRLS scores, sleep quality, and quality of life.
Gabapentinoids showed the largest reductions in RLS symptom severity.
Dopaminergic agents, while beneficial, had a higher risk of adverse events.
Iron therapy provided moderate benefits with good tolerability.
No treatment affected dialysis adequacy.
Clinical Implications
Healthcare providers should consider gabapentinoids as a first-line treatment for RLS in hemodialysis patients due to their efficacy in symptom management. It is essential to monitor for adverse events, particularly with dopaminergic agents, and to individualize treatment plans based on patient needs and tolerability.
Conclusion
The findings underscore the effectiveness of Western pharmacological agents, particularly gabapentinoids, in managing RLS among hemodialysis patients. Future research should focus on high-quality trials of Traditional Chinese Medicine to explore its potential benefits in this population.
